Connect with us

CBD News

Australian Regulators Advised To Reduce Complexities With Medical Cannabis Licensing Requirements

Published

on

Australian-Regulators-Advised-to-Reduce-Complexities-with-Medical-Cannabis-Licensing-Requirements

A recent government-commissioned report by Canberra’s Australian National University’s law professor, John McMillan, lists a number of recommendations to help the medical cannabis industry in Australia reports Marijuana Business Daily.

McMillan was supposedly hired to look closely at the regulatory barriers that the medical cannabis industry in Australia faces. One of the major concerns for the country rests in the ratio of actual licenses approved and total applications received, making the figure very small.

For instance, of the 246 license applications submitted this summer alone, only 24 licenses have allegedly been granted, with 16 for research and 23 for manufacturing purposes. This is apparently only the beginning of a long list of things officials need to consider.

Here is an overview of the recommendations provided in relation to medical cannabis by McMillan:

  1. Combine cultivation, manufacturing and research licenses into one license to reduce complexity in requirements and extraneous paperwork.

As per McMillan, this would eliminate, “information overload,” which otherwise results in the “(Office of Drug Control) ODC taking close to two years to process applications.”

  1. Extend the expiry dates on medical cannabis, research and manufacturing licenses to a maximum of five years
  2. Reassess ODC’s procedures to meet the need of existing license holders
  3. Creating a system in which those who already hold a medical cannabis license can easily get a manufacturing license
  4. Setting up industry consultation forums

The report doesn’t stop there, as the law professor also made recommendations regarding the country’s perspective on cannabidiol (CBD). In particular, he wants CBD to be de-scheduled from the 2016 Narcotic Drugs Regulation, so that an ODC licence is not required for the use of pure CBD as an ingredient.

On that note, McMillan urges that the improvements be made “as early as practicable.” When the news outlet reached out to the professor regarding his comment on timing, he simply said:

“I will leave it to the government to decide whether and how to implement my recommendations.”

Mandi brings an uplifting presence with universal experience to the COR team by hosting an honorable 11-year track record of elbow-greased content writing while adding in 20 years of expertise in business administration. This unique combination of wit and will is exactly what makes this site and all of our valued readers so special.

Continue Reading

Ultimate CBD Guide


Disclaimer

ultimate-cbd-products-company-guidepopular-cbd-health-benefits best-cannabidiol-guide-resources hemp guide

TimesofCBD is the most active daily CBD news publication featuring the latest cannabis industry stories and marijuana market trends. As the leader in CBD-centric content curation, we invite all readers to come for the headlines and stay for the insights. Quality is the top priority when presenting user guides, analyzing product reviews and reporting fact-checked news announcements. All information is for educational and informational purposes only. Disclaimer.

Got news? Email contact@timesofcbd.com

Copyright © 2020 TimesofCBD.com | Latest CBD News, Cannabis Guides and Marijuana Trends
Note: Always seek real additional medical advice and consultation with a professional healthcare practitioner before considering any CBD. No statements found on this website have underwent Food and Drug Administration evaluation. The efficacy of any products or claims made have never been approved by the FDA either. No products shall ever be intended to diagnose, treat or cure any disease or prevent any ailment.